This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kroemer, H. K. Articles by Eichelbaum, M. Search for Related Content PubMed PubMed Citation Articles by Kroemer, H. K. Articles by Eichelbaum, M.

Circulation, Vol 89, 2396-2400, Copyright © 1994 by American Heart Association

ARTICLES

An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy

HK Kroemer, MF Fromm, K Buhl, H Terefe, G Blaschke and M Eichelbaum
Dr Margarete Fischer-Bosch-Institut fur Klinische, Pharmakologie, Stuttgart, Germany.

BACKGROUND: Therapy with racemic compounds produces effects that can be attributed to both (S)- and (R)-enantiomers. Here we have tested the hypothesis that an enantiomer-enantiomer interaction would modulate the effects of treatment with a racemate, the antiarrhythmic propafenone. Previous studies have shown that while the enantiomers of propafenone exert similar sodium channel-blocking (QRS widening) effects, it is the (S)-enantiomer that produces beta-blockade; moreover, we have demonstrated recently that (R)-propafenone inhibits the metabolism of (S)-propafenone in vitro. METHODS AND RESULTS: This single-blind, randomized study compared the effects of (R/S)-, (S)-, (R)-propafenone (150 mg q 6 hours for 4 days) and placebo on QRS duration (delta QRS) and on maximum exercise heart rate (delta HRmax), an index of beta- blockade. The clearance of (S)-propafenone was significantly lower (-55 +/- 24%, P < .001) during treatment with (R/S)-propafenone than with the (S)-enantiomer alone, and delta HRmax was significantly altered during (R/S)-propafenone (-8.8 +/- 6.6 beats per minute; P < .01) and during (S)-propafenone (-4.3 +/- 4.8 beats per minute; P < .01) but not during (R)-propafenone (-1.8 +/- 6.4 beats per minute) or placebo (0.3 +/- 7.1 beats per minute). In contrast, (R/S)-, (S)-, and (R)- propafenone all prolonged QRS compared with placebo. CONCLUSIONS: These data indicate that (R)-propafenone impairs the disposition of (S)- propafenone in humans. As a result, the beta-blocking effects of 150 mg of racemic propafenone (75 mg of the [S]-enantiomer) were more pronounced than those of 150 mg of (S)-propafenone alone. Thus, the effects of racemic drug therapy are not necessarily those predicted by summation of the effects of the individual enantiomers.

This article has been cited by other articles:

				T. D. Bjornsson, J. A. Wagner, S. R. Donahue, D. Harper, A. Karim, M. S. Khouri, W. R. Murphy, K. Roman, D. Schneck, D. S. Sonnichsen, et al. A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness J. Clin. Pharmacol., September 1, 2003; 43(9): 943 - 967. [Abstract] [Full Text] [PDF]

				Z. Desta, N. Soukhova, A. M Morocho, and D. A Flockhart Stereoselective Metabolism of Cisapride and Enantiomer-Enantiomer Interaction in Human Cytochrome P450 Enzymes: Major Role of CYP3A J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 508 - 520. [Abstract] [Full Text] [PDF]

				R. Valdes Jr., S. A. Jortani, and M. Gheorghiade Standards of laboratory practice: cardiac drug monitoring Clin. Chem., May 1, 1998; 44(5): 1096 - 1109. [Abstract] [Full Text] [PDF]